Myeloma Paper of the Day, November 23rd, suggested by Robert Orlowski
Robert Orlowski shared a post on X:
“Myeloma Paper of the Day: MRD-driven phase 2 study of Dara/car/len/dex in newly diagnosed myeloma did meet not the primary endpoint, though Dara-KRd regimen strongly activated memory T cells, which was associated with an MRD-negative state.”
Authors: Manisha Bhutani, Myra Robinson, David Foureau, Shebli Atrash, Barry A Paul, Fei Guo, Jason Grayson, Anna Ivanina-Foureau, Mauricio Pineda-Roman, Cindy Varga, Reed Friend, Christopher J Ferreri, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B Anderson, James T Symanowski, Peter M Voorhees, Saad Z Usmani.
More posts featuring Robert Orlowski.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023